CHMP recommends Egranli for prophylaxis of Chemotherapy - induced Neutropenia - Teva
On 25 September 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Egranli, 40 mg, solution for injection intended for prophylaxis against chemotherapy-induced neutropenia. The applicant for this medicinal product is Teva Pharma B.V.
The active substance of Egranli is balugrastim, an immunostimulating medicinal product (L03AA15) which regulates the production and release of functional neutrophils from the bone marrow.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.